Status:
RECRUITING
Quantitative Xylazine Measurement in ED
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Overdose
Substance Use Disorders
Eligibility:
All Genders
18+ years
Brief Summary
Quantitative Xylazine Measurement Among Non-Fatal Opioid Overdose (OD) Patients in the Emergency Department (ED)
Detailed Description
Xylazine, a veterinary medication and alpha-2 agonist drug with clinical effects including prolonged sedation and skin/soft tissue wounds, has been increasingly detected with fentanyl in the illicit o...
Eligibility Criteria
Inclusion
- ED patient
- Opioid OD (both NPS and non-NPS)
- Availability of waste blood specimens for analysis
- Availability of waste urine specimens for analysis
Exclusion
- \- Children under 18
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 24 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06949605
Start Date
April 1 2025
End Date
February 24 2026
Last Update
May 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
NYC Health + Hospitals/Elmhurst
Elmhurst, New York, United States, 11373
2
Icahn School of Medicine
New York, New York, United States, 10029